Product | Patients | Conditioning regimen | CRS | ICANS | ORR/CR/CRi | PFS | OS | References |
---|---|---|---|---|---|---|---|---|
ssCART−19 | 47 | Fludarabine at 30mg/m2/day, cyclophosphamide at 300mg/m2/day on D−5,−4, and−3 | Grade 1–2 25/47 (53.20%) Grade 3–4 7/47 (14.89%) | Grade 1 2/47 (4.26%) | 91.49% CR/CRi on day 28 | mPFS 14.7 months | N/A | [5] |
WZTL−002 | 21 | Fludarabine (30 mg/m2/day) and cyclophosphamide (500mg/m2/day) on D−5,−4, and−3 | Grade 1–2 13/21 (62%) | No ICANS of any grade | 52% CR at 3 months | N/A | N/A | [6] |
19(T2)28z1XX | 28 | Fludarabine and cyclophosphamide | Grade 1–2 24/28 (86%) Grade 3 1/28 (4%) | Grade 1–2 1/28 (4%) Grade 3 2/28 (7%) | 82% ORR 71% CR | N/A | N/A | [7] |
BRL−201 | 21 | Cyclophosphamide (500mg/m2, D−3 to−2) and fludarabine (30mg/m2, D−4 to−2) | Grade 1–2 14/21 (66.7%) | Grade 1–2 4/21 (19.0%) | 100% ORR 85.7% CR | mPFS 20.8 months | 76.2% 12-month OS | [8] |
UCART20×22 | 3 | Fludarabine 30 mg/m2 × 3d, cyclophosphamide 0.5 g/m2 × 3d, alemtuzumab 12 mg on D1, 24 mg on D2, D3 | Grade 1–2 3/3 (100%) | No ICANS of any grade | 66.7% CR on day 28 | N/A | N/A | [9] |
CD19/CD70 CAR T-cells | 8 | Cyclophosphamide and fludarabine chemotherapy conditioning 1–2 days | Grade 1–2 3/8 (37.5%) | No ICANS of any grade | 87.5% ORR 75.0% CR at 1 month | N/A | N/A | [10] |
C-CAR039 | 48 | Cyclophosphamide plus fludarabine chemotherapy conditioning 3 days | Grade 1–2 44/48 (91.7%) Grade 3 1/48 (2.1%) | Grade 1–2 3/48 (6.52%) | 91.5% ORR 85.1% CR | 66.0% 24-month PFS | 77.9% 24-month OS | [11] |
ONCT−808 | N/A | Cyclophosphamide and fludarabine | N/A | N/A | N/A | N/A | N/A | [12] |